End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
40.25 THB | 0.00% | -0.62% | 0.00% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- This company will be of major interest to investors in search of a high dividend stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company appears highly valued given the size of its balance sheet.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
0.00% | 970M | B | ||
+32.09% | 694B | C+ | ||
+29.39% | 593B | B | ||
-1.34% | 371B | C+ | ||
+20.34% | 331B | B- | ||
+7.39% | 290B | C+ | ||
+14.25% | 239B | B+ | ||
-3.03% | 209B | A+ | ||
+10.02% | 209B | B- | ||
+8.49% | 169B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MEGA Stock
- Ratings Mega Lifesciences